Merck Acquires Life Sciences Company Bio-Techne

The transaction would bring together two highly complementary and leading life sciences organizations, uniquely positioned to support customers across the full spectrum of life science workflows – from discovery and translational research through research, testing and commercial manufacturing. Additionally, it would immediately deliver on Merck’s mid- to prolonged strategic agenda, which focuses on high-development value drivers, integrated workflows, platformed capabilities and scaling and sourcing innovation through M&A.

“This transaction is an crucial milestone towards delivering on our mid- to prolonged strategic agenda. Bio-Techne is an outstanding fit that immediately supports our strategic direction focused on delivering cutting-edge items and solutions across the entire sector value chain – from lab customers to those manufacturing in the biotech and medical industries,” said Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck. “By combining Bio-Techne’s scientific depth, innovation engine and differentiated portfolio with Merck’s global scale, manufacturing excellence and customer reach, we are in a strong position to address some of the most crucial opportunities in life sciences and support our customers in accelerating the next generation of scientific discovery and therapeutic innovation. This positions us to deliver compelling strategic and financial benefits to shareholders, customers and employees.”

“to 50 years, Bio-Techne has enabled scientific breakthroughs across proteomics, spatial biology, and novel therapeutics,” said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. “This transaction is a testament to the remarkable company our team has built and to the enduring value we create to our customers and stakeholders. As part of Merck, we will have greater scale and expanded capabilities to accelerate innovation and deepen our impact. Together, we will empower our customers to tackle the most crucial challenges in science and healthcare, helping to enhance outcomes worldwide.”

Bio-Techne is one of the leading providers of recombinant proteins, with 50 years of experience in the research and research of innovative technologies and new treatment methods. With Bio-Techne, Merck will expand its portfolio to include a globally established range of cytokines, development factors, antibodies, and immunoassay kits.

Headquartered in Minneapolis, Minnesota, the company employs greater than 3,000 people worldwide, including approximately 2,300 in the US. It has 34 locations and 15 production and manufacturing facilities in the US, Canada, the United Kingdom, Switzerland, and China, and generated revenue of greater than $1.2 billion in fiscal year 2025.

Merck KGaA

Company contact

Circular Plastics Economy

Enamine's Expert Insights Collection Is Free to Download

Safer, Scalable medical Manufacturing with Flow Chemistry

thorough Insights into Antibody–Drug Conjugates (ADC) to Precision Cancer Therapy

Siemens Joins the Global Impact Coalition

Upcoming Virtual Events

Operationalizing AI in Polymer research: How Syensqo Is Scaling Impact with the Citrine Platform

Predictive Simulation in Pharma Production

Capillary Electrophoresis in Biotherapeutic research: Platform Methods, Fragment Workflows, and ADC Characterization

Ratcliffe: Chemical sector in Europe at a Tipping Point

Dow to Shut Down Three Upstream European Assets

Orion Announced Plans to Shut Down Carbon Black vegetation

VCI Welcomes US-EU Customs Deal

BASF Sells Majority Stake in Coatings Business

Newsletter & e-edition